Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy (Adv. Mater. 22/2023)
Boda Guo, Feiya Yang, Lingpu Zhang, Qinxin Zhao, Wenkuan Wang, Lu Yin, Dong Chen, Mingshuai Wang, Sujun Han, Haihua Xiao, Nianzeng Xing
Abstract
Immunotherapy In article 2212267, Haihua Xiao, Nianzeng Xing, and co-workers present a novel therapeutic strategy to achieve synergistic cancer immunotherapy via cuproptosis induced by reactive oxygen species (ROS)-responsive nanomedicine loaded with elesclomol and copper ([email protected]). With this approach, the tumor microenvironment is reprogrammed, and the expression of PD-L1 is increased, which consequently improves responsiveness of immunotherapy.
Topics & Concepts
ImmunotherapyNanomedicineCancer researchCancer immunotherapyMaterials scienceTumor microenvironmentReactive oxygen speciesNanoparticleCancerNanotechnologyMedicineTumor cellsInternal medicineChemistryBiochemistryNanoplatforms for cancer theranosticsAdvanced Nanomaterials in CatalysisCancer, Stress, Anesthesia, and Immune Response